Dissociable effects of alzheimer disease and white matter hyperintensities on brain metabolism

JAMA Neurology

Volumn 70, Issue 8, 2013, Pages 1039-1045

  Haight, Thaddeus J ^a   Landau, Susan M ^a   Carmichael, Owen ^a   Schwarz, Christopher ^a   DeCarli, Charles ^a   Jagust, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; WHITE MATTER HYPERINTENSITY;

EID: 84882395407     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1878     Document Type: Article

References (39)

1. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study: the Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14.
2. Pugh KG, Lipsitz LA. The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging. 2002;23(3):421-431.
3. DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology. 1995;45(11):2077-2084.
4. Yoshita M, Fletcher E, DeCarli C. Current concepts of analysis of cerebral white matter hyperintensities onmagnetic resonance imaging. Top Magn Reson Imaging. 2005;16(6):399-407.
5. Nordahl CW, Ranganath C, Yonelinas AP, Decarli C, Fletcher E, JagustWJ. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J Cogn Neurosci. 2006;18(3):418-429.
6. JagustWJ, D'Esposito M. Imaging the Aging Brain. New York, NY: Oxford University Press; 2009.
7. JagustWJ, Zheng L, Harvey DJ, et al. Neuropathological basis ofmagnetic resonance images in aging and dementia. Ann Neurol. 2008;63(1):72-80.
8. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. http://www.ncbi.nlm.nih.gov/pubmed /20660506?dopt=Abstract. Accessed April 27, 2013.
9. Wright CB, Festa JR, Paik MC, et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke. 2008;39(3):800-805.
10. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123.
11. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci. 1999;893:113-125.
12. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363(9415):1139-1146.
13. Pascual B, Prieto E, Arbizu J, Marti-Climent J, Olier J, Masdeu JC. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer disease. Stroke. 2010;41(12):2889-2893.
14. Marchant NL, Reed BR, Decarli CS, et al Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging. 2012;33(5):1006.e25- 1006.e36.
15. Reed BR, Eberling JL, Mungas D,Weiner M, JagustWJ. Frontal lobe hypometabolism predicts cognitive decline in patients with lacunar infarcts. Arch Neurol. 2001;58(3):493-497.
16. TullbergM, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology. 2004;63(2):246-253.
17. Kuczynski B, JagustW, Chui HC, Reed B. An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology. 2009;72(8):738-743.
18. WeinerMW, Aisen PS, Jack CR Jr, et al. Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202-211.e7. http://www.ncbi .nlm.nih.gov/pmc/articles/PMC2927112/. Accessed April 29, 2013.
19. Carmichael O, Schwarz C, Drucker D, et al; Alzheimer's Disease Neuroimaging Initiative. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer Disease Neuroimaging Initiative. Arch Neurol. 2010;67(11):1370-1378.
20. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.
21. ADNI. Alzheimer's Disease Neuroimaging Initiative. http://www.adni-info. org/. Accessed August 22, 2011.
22. Jack CR Jr, Bernstein MA, Borowski BJ, et al; Alzheimer's Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2010;6(3):212-220.
23. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009;21:239-251.
24. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839-851.
25. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.
26. Trojanowski JQ, Vandeerstichele H, KoreckaM, et al; Alzheimer's Disease Neuroimaging Initiative. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6(3):230-238.
27. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-238.
28. Lo RY, Hubbard AE, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68(10):1257-1266.
29. Diggle P, Heagerty P, Kung-Yee L, Zeger S. Analysis of Longitudinal Data. 2nd ed. New York, NY: Oxford University Press; 2002.
30. Petkov CI,Wu CC, Eberling JL, et al. Correlates of memory function in community-dwelling elderly: the importance of white matter hyperintensities. J Int Neuropsychol Soc. 2004;10(3):371-381.
31. JagustWJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.
32. Jack CR Jr, Knopman DS, JagustWJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
33. Beckett LA, Harvey DJ, Gamst A, et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010;6(3):257-264.
34. Chen ST, Sultzer DL, Hinkin CH, Mahler ME, Cummings JL. Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci. 1998;10(4): 426-432.
35. Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Arch Neurol. 2004;61(4): 556-560.
36. Marshall GA, Rentz DM, Frey MT, Locascio JJ, Johnson KA, Sperling RA; Alzheimer's Disease Neuroimaging Initiative. Executive function and instrumental activities of daily living inmild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2011;7(3):300-308.
37. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
38. Thomas AJ, O'Brien JT, Barber R, McMeekinW, Perry R. A neuropathological study of periventricular white matter hyperintensities in major depression. J Affect Disord. 2003;76(1-3):49-54.
39. Teodorczuk A, O'Brien JT, Firbank MJ, et al; LADIS Group. White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry. 2007;191:212-217.